Answers are grounded in this paper and cite their sources.
Bacterial glycoconjugate vaccines contain capsule-derived bacterial polysaccharides chemically conjugated to carrier proteins and are highly immunogenic in the infant population for whom they were originally designed. This class of vaccine has shown a profound impact on the incidence of both invasive disease, such as septicaemia and meningitis, as well as mucosal infections including pneumonia and otitis media, in individuals who receive the vaccine. Unlike purified polysaccharide vaccines, glycoconjugates have also shown a profound indirect impact, reducing the incidence of disease in the unvaccinated population of all ages.
No takes yet. Share an insight, caveat, or question.
David Goldblatt (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: